These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


117 related items for PubMed ID: 2261137

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S, De Pasquale MP, Mainini F, Bulgheroni E, Kurtagic S, Gori A, Violin M, Zanchetta N, Moroni M, Balotta C, Galli M.
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [Abstract] [Full Text] [Related]

  • 23. Decline of HIV-1 RNA in cerebrospinal fluid during zidovudine treatment.
    Portegies P, Danner SA, Enting RH, Meilof J, de Wolf F, Goudsmit J.
    Antivir Ther; 1996 Aug; 1(3):195. PubMed ID: 11322255
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
    Rinaldo CR, Liebmann JM, Huang XL, Fan Z, Al-Shboul Q, McMahon DK, Day RD, Riddler SA, Mellors JW.
    J Infect Dis; 1999 Feb; 179(2):329-36. PubMed ID: 9878015
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
    Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, Talal A, Hurley A, Jin X, Chaudhry MR, Yaman M, Frankel S, Heath-Chiozzi M, Leonard JM, Moore JP, Racz P, Nixon DF, Ho DD.
    J Infect Dis; 1999 Mar; 179(3):527-37. PubMed ID: 9952358
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients.
    Casado JL, Valdezate S, Calderon C, Navas E, Frutos B, Guerrero A, Martinez-Beltran J.
    J Infect Dis; 1999 Jun 18; 179(6):1553-6. PubMed ID: 10228081
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Preliminary report of a multicentre study of zidovudine plus or minus acyclovir in patients with acquired immune deficiency syndrome or acquired immune deficiency syndrome-related complex.
    Fiddian AP.
    J Infect; 1989 Jan 18; 18 Suppl 1():79-80. PubMed ID: 2644364
    [No Abstract] [Full Text] [Related]

  • 38. AIDS treatment. Confusion over therapy.
    Aldhous P.
    Nature; 1992 Jan 09; 355(6356):102. PubMed ID: 1729639
    [No Abstract] [Full Text] [Related]

  • 39. The rocky road to effective treatment of human immunodeficiency virus (HIV) infection.
    Hirsch MS.
    Ann Intern Med; 1989 Jan 01; 110(1):1-3. PubMed ID: 2642281
    [No Abstract] [Full Text] [Related]

  • 40. [Neuromuscular manifestations of HIV-1 and HTLV-I infections].
    Hartung HP, Heininger K, Toyka KV.
    Dtsch Med Wochenschr; 1988 Dec 16; 113(50):1975-81. PubMed ID: 2848677
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 6.